Smith out as Angeion CEO

Angeion, which develops and markets devices to treat irregular heartbeats, has announced that Philip Smith has resigned as the company's CEO. The decision was a mutual one between Smith and the company's board of directors. Smith became president and CEO of the company effective January 1, 2011 pursuant to a letter agreement that provided for at-will employment. Gregg Lehman will serve as interim CEO, effective immediately. Angeion release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.